<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03095456</url>
  </required_header>
  <id_info>
    <org_study_id>0149</org_study_id>
    <nct_id>NCT03095456</nct_id>
  </id_info>
  <brief_title>Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD</brief_title>
  <official_title>A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler® on Lung Function in Subjects With COPD and a Low PIFR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, double-dummy, parallel group study to compare once
      daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung
      function in subjects with COPD and a Low Peak Inspiratory Flow Rate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Actual">November 25, 2017</completion_date>
  <primary_completion_date type="Actual">November 25, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough FEV1 on Day 29</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>FEV1 = forced expiratory volume at one second</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Trough FVC (Forced Vital Capacity) on Day 29</measure>
    <time_frame>Baseline and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Trough Inspiratory Capacity (IC) on Day 29</measure>
    <time_frame>Baseline and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Peak FEV1 on Day 29</measure>
    <time_frame>Baseline and Day 29 (0-4 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Peak FVC on Day 29</measure>
    <time_frame>Baseline and Day 29 (0-4 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Rescue Medication Use: Puffs Per Day</measure>
    <time_frame>1 Month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease, COPD</condition>
  <condition>Low Peak Inspiratory Flow Rate (PIFR)</condition>
  <arm_group>
    <arm_group_label>Revefenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Revefenacin and placebo (in place of Spiriva Handihaler®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva Handihaler®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Spiriva Handihaler® and placebo (in place of Revefenacin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revefenacin</intervention_name>
    <description>Revefenacin administered via nebulization.</description>
    <arm_group_label>Revefenacin</arm_group_label>
    <other_name>TD-4208</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Spiriva Handihaler®</intervention_name>
    <description>Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.</description>
    <arm_group_label>Spiriva Handihaler®</arm_group_label>
    <other_name>Tiotropium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Revefenacin</intervention_name>
    <description>Placebo administered as double blind, double dummy via nebulization.</description>
    <arm_group_label>Spiriva Handihaler®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Spiriva Handihaler®</intervention_name>
    <description>Placebo administered as double blind, double dummy via Spiriva HandiHaler®.</description>
    <arm_group_label>Revefenacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older with a diagnosis of COPD.

          -  Subject has a current or past cigarette smoking history (or equivalent for cigar or
             pipe smoking history) of at least 10 pack-years.

          -  Subject is willing and able to provide signed and dated written informed consent to
             participate prior to initiation of any study related procedures.

        Exclusion Criteria:

          -  Subject has a concurrent disease or condition that, in the opinion of the
             investigator, would interfere with continued study participation or confound the
             evaluation of safety and tolerability of the study drug.

          -  Subject has a history of reactions or hypersensitivity to inhaled or nebulized
             anticholinergics.

          -  Subject suffers from any medical condition that would preclude the use of inhaled
             anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic
             hyperplasia, bladder neck obstruction, or urinary retention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research of Rock Hill</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <results_first_submitted>December 6, 2018</results_first_submitted>
  <results_first_submitted_qc>December 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2018</results_first_posted>
  <disposition_first_submitted>September 20, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>September 20, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 25, 2018</disposition_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease, COPD</keyword>
  <keyword>Low Peak Inspiratory Flow Rate (PIFR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03095456/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03095456/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Revefenacin</title>
          <description>Active Revefenacin and placebo (in place of Spiriva Handihaler®)
Revefenacin: Revefenacin administered via nebulization.
Placebo for Spiriva Handihaler®: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.</description>
        </group>
        <group group_id="P2">
          <title>Spiriva Handihaler®</title>
          <description>Active Spiriva Handihaler® and placebo (in place of Revefenacin)
Spiriva Handihaler®: Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
Placebo for Revefenacin: Placebo administered as double blind, double dummy via nebulization.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>Revefenacin</title>
          <description>Active Revefenacin and placebo (in place of Spiriva Handihaler®)
Revefenacin: Revefenacin administered via nebulization.
Placebo for Spiriva Handihaler®: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.</description>
        </group>
        <group group_id="B2">
          <title>Spiriva Handihaler®</title>
          <description>Active Spiriva Handihaler® and placebo (in place of Revefenacin)
Spiriva Handihaler®: Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
Placebo for Revefenacin: Placebo administered as double blind, double dummy via nebulization.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="7.94"/>
                    <measurement group_id="B2" value="65.1" spread="8.36"/>
                    <measurement group_id="B3" value="65.1" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough FEV1 on Day 29</title>
        <description>FEV1 = forced expiratory volume at one second</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>Intent-to-treat (ITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Revefenacin</title>
            <description>Active Revefenacin and placebo (in place of Spiriva Handihaler®)
Revefenacin: Revefenacin administered via nebulization.
Placebo for Spiriva Handihaler®: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Handihaler®</title>
            <description>Active Spiriva Handihaler® and placebo (in place of Revefenacin)
Spiriva Handihaler®: Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
Placebo for Revefenacin: Placebo administered as double blind, double dummy via nebulization.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FEV1 on Day 29</title>
          <description>FEV1 = forced expiratory volume at one second</description>
          <population>Intent-to-treat (ITT) analysis set</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="20.17"/>
                    <measurement group_id="O2" value="47.3" spread="19.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Trough FVC (Forced Vital Capacity) on Day 29</title>
        <time_frame>Baseline and Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revefenacin</title>
            <description>Active Revefenacin and placebo (in place of Spiriva Handihaler®)
Revefenacin: Revefenacin administered via nebulization.
Placebo for Spiriva Handihaler®: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Handihaler®</title>
            <description>Active Spiriva Handihaler® and placebo (in place of Revefenacin)
Spiriva Handihaler®: Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
Placebo for Revefenacin: Placebo administered as double blind, double dummy via nebulization.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Trough FVC (Forced Vital Capacity) on Day 29</title>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.4" spread="38.75"/>
                    <measurement group_id="O2" value="55.8" spread="36.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Trough Inspiratory Capacity (IC) on Day 29</title>
        <time_frame>Baseline and Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revefenacin</title>
            <description>Active Revefenacin and placebo (in place of Spiriva Handihaler®)
Revefenacin: Revefenacin administered via nebulization.
Placebo for Spiriva Handihaler®: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Handihaler®</title>
            <description>Active Spiriva Handihaler® and placebo (in place of Revefenacin)
Spiriva Handihaler®: Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
Placebo for Revefenacin: Placebo administered as double blind, double dummy via nebulization.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Trough Inspiratory Capacity (IC) on Day 29</title>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" spread="42.33"/>
                    <measurement group_id="O2" value="84.1" spread="40.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Peak FEV1 on Day 29</title>
        <time_frame>Baseline and Day 29 (0-4 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revefenacin</title>
            <description>Active Revefenacin and placebo (in place of Spiriva Handihaler®)
Revefenacin: Revefenacin administered via nebulization.
Placebo for Spiriva Handihaler®: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Handihaler®</title>
            <description>Active Spiriva Handihaler® and placebo (in place of Revefenacin)
Spiriva Handihaler®: Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
Placebo for Revefenacin: Placebo administered as double blind, double dummy via nebulization.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Peak FEV1 on Day 29</title>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.2" spread="18.70"/>
                    <measurement group_id="O2" value="197.7" spread="17.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Peak FVC on Day 29</title>
        <time_frame>Baseline and Day 29 (0-4 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revefenacin</title>
            <description>Active Revefenacin and placebo (in place of Spiriva Handihaler®)
Revefenacin: Revefenacin administered via nebulization.
Placebo for Spiriva Handihaler®: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Handihaler®</title>
            <description>Active Spiriva Handihaler® and placebo (in place of Revefenacin)
Spiriva Handihaler®: Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
Placebo for Revefenacin: Placebo administered as double blind, double dummy via nebulization.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Peak FVC on Day 29</title>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.2" spread="37.35"/>
                    <measurement group_id="O2" value="340.1" spread="35.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Rescue Medication Use: Puffs Per Day</title>
        <time_frame>1 Month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revefenacin</title>
            <description>Active Revefenacin and placebo (in place of Spiriva Handihaler®)
Revefenacin: Revefenacin administered via nebulization.
Placebo for Spiriva Handihaler®: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Handihaler®</title>
            <description>Active Spiriva Handihaler® and placebo (in place of Revefenacin)
Spiriva Handihaler®: Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
Placebo for Revefenacin: Placebo administered as double blind, double dummy via nebulization.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Rescue Medication Use: Puffs Per Day</title>
          <units>puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.42"/>
                    <measurement group_id="O2" value="2.9" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of ICF through the final follow-up assessment (approximately 1 month).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Revefenacin</title>
          <description>Active Revefenacin and placebo (in place of Spiriva Handihaler®)
Revefenacin: Revefenacin administered via nebulization.
Placebo for Spiriva Handihaler®: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.</description>
        </group>
        <group group_id="E2">
          <title>Spiriva Handihaler®</title>
          <description>Active Spiriva Handihaler® and placebo (in place of Revefenacin)
Spiriva Handihaler®: Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
Placebo for Revefenacin: Placebo administered as double blind, double dummy via nebulization.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Development &amp; Medical Affairs</name_or_title>
      <organization>Theravance Biopharma</organization>
      <phone>1-855-633-8479</phone>
      <email>medinfo@theravance.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

